Neuland Laboratories Ltd
NSE:NEULANDLAB
Neuland Laboratories Ltd
NSE:NEULANDLAB
Price:
13 109
INR
5.44%
Market Closed
Market Cap:
₹168.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Neuland Laboratories Ltd
NSE:NEULANDLAB
|
IN |
|
Champion Real Estate Investment Trust
HKEX:2778
|
HK |
|
O Bank Co Ltd
TWSE:2897
|
TW |
|
BNP Paribas SA
PAR:BNP
|
FR |
|
C
|
Campbell Soup Co
SWB:CSC
|
US |
|
H
|
Hydrogene De France SA
PAR:HDF
|
FR |
|
Johnson Service Group PLC
LSE:JSG
|
UK |
|
S
|
Shenzhen FRD Science & Technology Co Ltd
SZSE:300602
|
CN |
|
Abundante Ltd
SGX:570
|
SG |
|
Corporacion Acciona Energias Renovables SA
MAD:ANE
|
ES |
|
Bega Cheese Ltd
ASX:BGA
|
AU |
|
G
|
Greenland Resources Inc
OTC:GRLRF
|
CA |
|
Chang Hwa Commercial Bank Ltd
TWSE:2801
|
TW |
|
S
|
STWC Holdings Inc
OTC:STWC
|
US |
|
H
|
Highlands REIT Inc
OTC:HHDS
|
US |
|
S
|
Shengjing Bank Co Ltd
HKEX:2066
|
CN |
|
Spirax-Sarco Engineering PLC
LSE:SPX
|
UK |
Multiples-Based Value
The Multiples-Based Value of one
NEULANDLAB
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 13 109 INR,
Neuland Laboratories Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NEULANDLAB Multiples-Based Value
LOCKED
Multiples Across Competitors
NEULANDLAB Competitors Multiples
Neuland Laboratories Ltd Competitors
Neuland Laboratories Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Neuland Laboratories Ltd
NSE:NEULANDLAB
|
159.5B INR | 10.7 | 93.9 | 54.2 | 71.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 13.4 | 42.4 | 28.6 | 30.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
580.2B USD | 6.2 | 21.6 | 15 | 18.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.2B USD | 2.5 | 20.4 | 7.8 | 10.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.4B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
